[CLSTR]
< Back to situation

[REVISION HISTORY]

India FMCG earnings mixed in Q1 FY27, HUL profit dip

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-07-29 15:40 UTC → 2026-07-30 06:55 UTC · added removed

India FMCG earnings stay mixed in Q1 FY27 FY27, HUL profit dip

July‑August earnings filings reinforce a fragmented picture for keep India’s fast‑moving consumer goods (FMCG) and health‑related firms. sectors on a fragmented footing. Nestlé India confirmed posted a 47.9% net‑profit profit jump to ₹975 crore, with sales up 25.4% and exports rising 35.6% despite geopolitical headwinds, 35.6%, and announced a €3 billion cash raise by spinning as it spins off its bottled‑water business into a 50:50 JV joint venture with Platinum Equity (new entity Peranel). Granules India again reported delivered a near‑60% profit surge, driven by margin expansion and a 22% revenue rise. growth. Hindustan Unilever posted a 10% Unilever’s revenue increase rose about 10% to roughly ₹17.3 trillion ₹17.34 trillion, but saw consolidated net profit slip about fell 3% to ₹2,673 crore, a dip attributed year‑on‑year to a one‑off tax credit and higher input costs. roughly ₹2,673‑2,680 crore. The stock fell ~6% on the news before partially recovering as analysts noted the company absorbed half of a an estimated 10% cost inflation. input‑cost inflation, passing only a 5% price rise to consumers and leaning on volume‑led growth (underlying volume up 5%). EBITDA climbed 8% to ₹3,947 crore, keeping the margin near 23%. Shares slipped nearly 6% on the earnings day but rebounded about 4% intraday, ending the session up roughly 3.9%. Several brokerages upgraded the stock, setting target prices between ₹2,450 and ₹2,850 and labeling it bullish despite the profit miss. Pharma and health‑retail firms faced pressure: Cipla’s profit fell 39.2% 39% to ₹7.89 billion, hampered by weaker U.S. sales of a generic cancer drug and supply disruptions after an FDA inspection of its sole supplier. Dr Reddy’s Laboratories posted saw a 69% profit plunge to ₹4,435 crore, also due to semaglutide supply issues and weaker North‑American sales. MedPlus Health Services’ profit declined reported a 22% profit decline to ₹331.8 million, citing higher expansion costs and intensifying competition. Other large corporates showed mixed outcomes: Meanwhile, Larsen & Toubro reported posted a 14% PAT rise; rise and Asian Paints posted a 40% profit jump; jump, while Vedanta Power logged recorded a loss. Overall, domestic Domestic demand and export momentum buoy sustain a few FMCG leaders, but pharma and health‑retail players continue to face margin pressure stress and operational setbacks. setbacks linger for pharma and health‑retail players.

Versions

  1. 2026-07-30 06:55 UTC India FMCG earnings mixed in Q1 FY27, HUL profit dip
  2. 2026-07-29 15:40 UTC India FMCG earnings stay mixed in Q1 FY27

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.